SCHEMBL5334602

SCHEMBL5334602

CC(C)S(=O)(=O)Nc1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.46
NAMPT P43490 1/20 0.46
MAPK1 P28482 2/20 0.46
POLB P06746 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 4/20 0.45
NPSR1 Q6W5P4 2/20 0.45
GPR119 Q8TDV5 1/20 0.44
SMARCA2 P51531 1/20 0.44
SMARCA4 P51532 1/20 0.44
PBRM1 Q86U86 1/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
MAPT P10636 2/20 0.44
STS P08842 2/20 0.44
NPC1 O15118 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5338059 0.90 GLA (0.44) BACE1NAMPTMAPK1POLBCASP1
SCHEMBL4513123 0.88 NPY5R (0.48) BACE1NAMPTMAPK1POLBCASP1
SCHEMBL5336031 0.86 STS (0.48) BACE1NAMPTALDH1A1GPR119SMARCA2
SCHEMBL14387753 0.85 BACE1 (0.46) BACE1NAMPTALDH1A1GPR119SMARCA2
SCHEMBL5336255 0.85 MCOLN3 (0.62) STSL3MBTL1MEN1KMT2A
SCHEMBL23379599 0.84 MCOLN3 (0.53) MAPK1POLBALDH1A1MAPTSTS
SCHEMBL6603122 0.84 GPR119 (0.46) BACE1NAMPTGPR119SMARCA2SMARCA4
SCHEMBL23379772 0.83 TGFBR1 (0.52) BACE1NAMPTHSD17B10ALDH1A1NPSR1
SCHEMBL5337500 0.82 ALDH1A1 (0.67) BACE1NAMPTMAPK1POLBCASP1
SCHEMBL5340137 0.82 STS (0.61) BACE1ALDH1A1NPSR1GPR119SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R BACE1 4081/4885NAMPT 801/4885MAPK1 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.